These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
383 related articles for article (PubMed ID: 31507593)
1. Systemic Inflammation and the Increased Risk of Inflamm-Aging and Age-Associated Diseases in People Living With HIV on Long Term Suppressive Antiretroviral Therapy. Babu H; Ambikan AT; Gabriel EE; Svensson Akusjärvi S; Palaniappan AN; Sundaraj V; Mupanni NR; Sperk M; Cheedarla N; Sridhar R; Tripathy SP; Nowak P; Hanna LE; Neogi U Front Immunol; 2019; 10():1965. PubMed ID: 31507593 [TBL] [Abstract][Full Text] [Related]
2. Risk factors for delayed viral suppression on first-line antiretroviral therapy among persons living with HIV in Haiti, 2013-2017. Rich SN; Cook RL; Yaghjyan L; Francois K; Puttkammer N; Robin E; Bae J; Joseph N; Pessoa-Brandão L; Delcher C PLoS One; 2020; 15(10):e0240817. PubMed ID: 33119631 [TBL] [Abstract][Full Text] [Related]
3. Distinct Lipidomic Signatures in People Living With HIV: Combined Analysis of ACTG 5260s and MACS/WIHS. Jao J; Balmert LC; Sun S; McComsey GA; Brown TT; Tien PC; Currier JS; Stein JH; Qiu Y; LeRoith D; Kurland IJ J Clin Endocrinol Metab; 2022 Jan; 107(1):119-135. PubMed ID: 34498048 [TBL] [Abstract][Full Text] [Related]
4. Managing HIV-associated inflammation and ageing in the era of modern ART. Bloch M; John M; Smith D; Rasmussen TA; Wright E HIV Med; 2020 Oct; 21 Suppl 3():2-16. PubMed ID: 33022087 [TBL] [Abstract][Full Text] [Related]
5. Preservation of Gastrointestinal Mucosal Barrier Function and Microbiome in Patients With Controlled HIV Infection. Mak G; Zaunders JJ; Bailey M; Seddiki N; Rogers G; Leong L; Phan TG; Kelleher AD; Koelsch KK; Boyd MA; Danta M Front Immunol; 2021; 12():688886. PubMed ID: 34135912 [TBL] [Abstract][Full Text] [Related]
6. Impact of aging on neurocognitive performance in previously antiretroviral-naive HIV-infected individuals on their first suppressive regimen. Coban H; Robertson K; Smurzynski M; Krishnan S; Wu K; Bosch RJ; Collier AC; Ellis RJ AIDS; 2017 Jul; 31(11):1565-1571. PubMed ID: 28471765 [TBL] [Abstract][Full Text] [Related]
7. Prevalence of metabolic syndrome among antiretroviral-naive and antiretroviral-experienced HIV-1 infected Thai adults. Jantarapakde J; Phanuphak N; Chaturawit C; Pengnonyang S; Mathajittiphan P; Takamtha P; Dungjun N; Pinyakorn S; Pima W; Prasithsirikul W; Phanuphak P AIDS Patient Care STDS; 2014 Jul; 28(7):331-40. PubMed ID: 24914459 [TBL] [Abstract][Full Text] [Related]
8. [Consensus document of Gesida and Spanish Secretariat for the National Plan on AIDS (SPNS) regarding combined antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2012)]. Panel de expertos de Gesida y Plan Nacional sobre el Sida Enferm Infecc Microbiol Clin; 2012 Jun; 30(6):e1-89. PubMed ID: 22633764 [TBL] [Abstract][Full Text] [Related]
9. Plasma soluble factor following two decades prolonged suppressive antiretroviral therapy in HIV-1-positive males: A cross-sectional study. Sperk M; Zhang W; Nowak P; Neogi U Medicine (Baltimore); 2018 Feb; 97(5):e9759. PubMed ID: 29384862 [TBL] [Abstract][Full Text] [Related]
10. Peripheral immune dysregulation in the ART era of HIV-associated neurocognitive impairments: A systematic review. Williams ME; Ipser JC; Stein DJ; Joska JA; Naudé PJW Psychoneuroendocrinology; 2020 Aug; 118():104689. PubMed ID: 32479968 [TBL] [Abstract][Full Text] [Related]
11. Plasma Inflammatory Biomarkers Predict CD4+ T-cell Recovery and Viral Rebound in HIV-1 Infected Africans on Suppressive Antiretroviral Therapy. Kroeze S; Rossouw TM; Steel HC; Wit FW; Kityo CM; Siwale M; Akanmu S; Mandaliya K; De Jager M; Ondoa P; Reiss P; Rinke De Wit TF; Kootstra NA; Hamers RL J Infect Dis; 2021 Aug; 224(4):673-678. PubMed ID: 33373447 [TBL] [Abstract][Full Text] [Related]
12. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial. Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E; Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227 [TBL] [Abstract][Full Text] [Related]
13. Brief Report: No Evidence for an Association Between Statin Use and Lower Biomarkers of HIV Persistence or Immune Activation/Inflammation During Effective ART. Bedimo RJ; Mar H; Bosch RJ; Drechsler H; Cyktor JC; Macatangay BJC; Lalama C; Rinaldo C; Collier A; Godfrey C; Hogg E; Hensel C; Eron JJ; Mcmahon DK; Mellors JW; Tebas P; Gandhi RT; J Acquir Immune Defic Syndr; 2019 Oct; 82(2):e27-e31. PubMed ID: 31335587 [TBL] [Abstract][Full Text] [Related]
14. Comparative impact of antiretroviral drugs on markers of inflammation and immune activation during the first two years of effective therapy for HIV-1 infection: an observational study. Hattab S; Guihot A; Guiguet M; Fourati S; Carcelain G; Caby F; Marcelin AG; Autran B; Costagliola D; Katlama C BMC Infect Dis; 2014 Mar; 14():122. PubMed ID: 24589015 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of dolutegravir-based regimens in advanced HIV-infected naïve patients: results from a multicenter cohort study. Rossetti B; Baldin G; Sterrantino G; Rusconi S; De Vito A; Giacometti A; Gagliardini R; Colafigli M; Capetti A; d'Ettorre G; Celani L; Lagi F; Ciccullo A; De Luca A; Di Giambenedetto S; Madeddu G Antiviral Res; 2019 Sep; 169():104552. PubMed ID: 31283942 [TBL] [Abstract][Full Text] [Related]
16. Increased monocyte activation with age among HIV-infected long term non-progressor children: implications for early treatment initiation. D'Souza RR; Gopalan BP; Rajnala N; Phetsouphanh C; Shet A HIV Med; 2019 Sep; 20(8):513-522. PubMed ID: 31131542 [TBL] [Abstract][Full Text] [Related]
17. Pre-therapy inflammation and coagulation activation and long-term CD4 count responses to the initiation of antiretroviral therapy. Achhra AC; Phillips A; Emery S; MacArthur RD; Furrer H; De Wit S; Losso M; Law MG; HIV Med; 2015 Aug; 16(7):449-54. PubMed ID: 25959989 [TBL] [Abstract][Full Text] [Related]
18. Safety and Effectiveness of Highly Active Antiretroviral Therapy in Treatment-Naïve HIV Patients: Preliminary Findings of a Cohort Event Monitoring Study in Belarus. Setkina S; Dotsenko M; Bondar S; Charnysh I; Kuchko A; Kaznacheeva A; Kozorez E; Dodaleva A; Rossa N Drug Saf; 2015 Apr; 38(4):365-72. PubMed ID: 25808626 [TBL] [Abstract][Full Text] [Related]
19. Adherence to antiretroviral therapy (ART) among people living with HIV (PLHIV): a cross-sectional survey to measure in Lao PDR. Hansana V; Sanchaisuriya P; Durham J; Sychareun V; Chaleunvong K; Boonyaleepun S; Schelp FP BMC Public Health; 2013 Jun; 13():617. PubMed ID: 23809431 [TBL] [Abstract][Full Text] [Related]
20. Antiretroviral therapy in older people with HIV. Richterman A; Sax PE Curr Opin HIV AIDS; 2020 Mar; 15(2):118-125. PubMed ID: 31990705 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]